GSK plc (GLAXF)
| Market Cap | 68.52B |
| Revenue (ttm) | 41.97B |
| Net Income (ttm) | 3.37B |
| Shares Out | n/a |
| EPS (ttm) | 0.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.57 (3.40%) |
| Ex-Dividend Date | Nov 14, 2024 |
| Volume | 232 |
| Open | 17.00 |
| Previous Close | 16.85 |
| Day's Range | 16.63 - 17.00 |
| 52-Week Range | 15.77 - 23.00 |
| Beta | 0.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2024 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled... [Read more]
Financial Performance
In 2023, GSK plc's revenue was 30.33 billion, an increase of 3.42% compared to the previous year's 29.32 billion. Earnings were 4.93 billion, a decrease of -67.05%.
Financial numbers in GBP Financial StatementsNews
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease.
GSK reports positive Phase 3 results for linerixibat in PBC itching
GSK share price is imploding: is it safe to buy the dip?
The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock retreated for five consecutive weeks and reached its lowest level since October las...
GSK drug meets main goal in late-stage study to treat relentless itch
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare autoimmun...
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De...
Vaccine stocks hit by Robert Kennedy Jr nomination
GSK, Sanofi and Moderna shares all sink after Donald Trump chooses vaccine sceptic as top US health official
GSK plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)
GSK plc (NYSE:GSK) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ETCompany ParticipantsEmma Walmsley - Chief Executive...
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
Pharma shares hit as Trump picks RFK Jr to lead health department
Appointment of vaccine critic knocks some of world’s biggest drugmakers including Moderna, AstraZeneca and GSK Who is RFK Jr and what are his likely top priorities? Business live – latest updates Inve...
Vaccine maker stocks fall on reports Trump plans to tap RFK Jr. to lead HHS
Shares of Moderna, Novavax, Pfizer, BioNTech and GSK closed lower on Thursday.
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
On Thursday, GSK plc (NYSE: GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with bortezomib ...
GSK hails progress for withdrawn blood cancer drug
UK pharma group posts ‘statistically significant’ trial results for Blenrep when combined with another treatment
GSK's Blenrep Shows Promise in Combination Therapy for Blood Cancer
GSK's Blenrep Shows Promise in Combination Therapy for Blood Cancer
GSK’s Withdrawn Blood Cancer Drug Paves Path Back to Market
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, further boosting the prospects of bringing the previously withdrawn medicine bac...
RFK Jr.'s Impact on Healthcare Policy: Investors Weigh Risks and Opportunities
Emily Field from Barclays and Lance Wilks share insights on how RFK Jr.'s influence could affect stocks in the pharmaceutical and healthcare sectors, including companies like GSK, Sanofi, and Novo Nor...
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia
Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who have moderate to severe anemia and other key manifestations associated with...
GSK lowered to hold by Jefferies, valuation disconnect cited
GSK Steps Up Parkinson’s Focus With US Biotech Deal
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug development for Parkinson’s disease.
Canada approves GSK's RSV vaccine for adults aged 50 to 59
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age ...
DHA and GSK sign a collaboration agreement to raise awareness on adult immunization
Tackling adult immunization education and awareness during the Healthcare Future Summit
GSK Pharma sets record date for Rs 12 special interim dividend on November 7, 2024
GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) has announced the record date for its special interim dividend, set for November 7, 2024. This follows the company’s earlier declaration on October...